You are about to be redirected to Xellia’s global website
We are now redirecting you to our global website, click ‘confirm’ below to continue or ‘cancel’ and we will return you to your previous page.
Cancel ConfirmClick here to see full
Prescribing Information
including BOXED WARNING.
We're committed to providing information and support to make implementing VANCO READY®
simple. Browse our library of resources for more information.
Read about clinical experience and guidance about several topics-including successful implementation of VANCO READY® and Covid-19.
White Paper Library
Virginia Mason Institute (VMI) is a consulting arm of Virginia Mason Franciscan Health. Xellia had the unique opportunity to partner with VMI, to conduct an extensive review of several processes within an acute care hospital focusing on workflows involving the inpatient pharmacy team.
The study has enabled us to gather detailed perspective into the value of pre-mixes in the hospital and pharmacy environment.
Download
Discover in-depth premix vancomycin injection information including risks, benefits, clinical data, safety considerations, and implementation strategies.
DownloadLearn best practices and get how-to information for implementing VANCO READY® into existing Cerner, EPIC, and Meditech systems.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
VANCOMYCIN INJECTION, safely and effectively. See full prescribing
information for VANCOMYCIN INJECTION.
VANCOMYCIN injection, for intravenous use
Initial U.S. Approval: 1958
RECENT MAJOR CHANGES
Boxed Warning 10/2021
Warnings and Precautions, Severe Dermatologic Reactions (5.5) 5/2021
Warnings and Precautions, Potential Risk of Exposure to Excipients During the First or Second Trimester of Pregnancy (5.1) 10/2021
WARNING: POTENTIAL RISK OF EXPOSURE TO EXCIPIENTS DURING THE FIRST OR SECOND TRIMESTER OF PREGNANCY
See full prescribing information for complete boxed warning.
If use of vancomycin is needed during the first or second trimester of pregnancy, use other available formulations of vancomycin. This formulation of vancomycin injection contains the excipients polyethylene glycol (PEG 400) and N-acetyl D-alanine (NADA), which resulted in fetal malformations in animal reproduction studies at dose exposures approximately 8 and 32 times, respectively, higher than the exposures at the human equivalent dose (5.1, 8.1).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Injection and other antibacterial drugs, Vancomycin Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.6)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Vancomycin Injection, USP: Single-dose flexible bags containing 500 mg vancomycin in 100 mL, 750 mg vancomycin in 150 mL, 1 g vancomycin in 200 mL, 1.25 g vancomycin in 250 mL, 1.5 g vancomycin in 300 mL, 1.75 g vancomycin in 350 mL and 2 g vancomycin in 400 mL of liquid. (3)
Hypersensitivity to vancomycin (4)
WARNINGS AND PRECAUTIONSADVERSE REACTIONS
The common adverse reactions are anaphylaxis, “red man syndrome”, acute kidney injury, hearing loss, neutropenia. (6.1)